Stay updated with breaking news from Nasdaq Sage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sage Therapeutics (NASDAQ:SAGE – Free Report) had its price objective decreased by JPMorgan Chase & Co. from $29.00 to $28.00 in a report published on Wednesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the stock. […]
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target decreased by analysts at Royal Bank of Canada from $26.00 to $15.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential […]
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective decreased by stock analysts at Truist Financial from $22.00 to $18.00 in a report released on Friday, Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Truist Financial’s target price indicates a potential upside of 31.48% from the stock’s […]
StockNews.com upgraded shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) from a sell rating to a hold rating in a research note published on Saturday morning. Several other analysts also recently commented on SAGE. Truist Financial lowered their price objective on Sage Therapeutics from $22.00 to $18.00 and set a hold rating for the company […]
Sage Therapeutics (NASDAQ:SAGE – Free Report) had its target price decreased by Truist Financial from $22.00 to $18.00 in a research report sent to investors on Friday, Benzinga reports. Truist Financial currently has a hold rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on SAGE. Canaccord Genuity Group decreased their price […]